Deutsche Bank Maintains a 'Buy' on Alexion Pharmaceuticals (ALXN); aHUS in the Books - Dry AMD & NMO Next - Value Left

Deutsche Bank maintains a 'Buy' on Alexion Pharmaceuticals (NASDAQ: ALXN) raises price target to $78.00.

Deutsche analyst says, "Recently, Soliris received FDA approval & positive opinion in EU for its 2nd indication, aHUS & showed activity in MG. These are just the latest achievements in Alexion's run but lead to the question from investors, What's next? Answer: Proof of concept data in NMO & dry AMD in '12E. Based on our work, we have begun to assign value to these new indications & believe there remains significant value on the table."

For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $66.18 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• DA Davidson Reiterates Neutral Rating on Timken (TKR)